DDInter810 DDInter1376
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Gefitinib {u} (Compound) resembles {v} (Compound) Erlotinib
Gefitinib {u} (Compound) treats {v} (Disease) lung cancer
Gefitinib {u} (Compound) binds {v} (Gene) CYP2D6
Gefitinib {u} (Compound) upregulates {v} (Gene) ZNF589
Gefitinib {u} (Compound) downregulates {v} (Gene) IFRD2
Gefitinib {u} (Compound) causes {v} (Side Effect) Appetite absent
Gefitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Danazol
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Gefitinib (Compound) resembles Bosutinib (Compound)
Gefitinib (Compound) resembles Erlotinib (Compound)
Gefitinib (Compound) treats lung cancer (Disease)
Gefitinib (Compound) binds CYP2D6 (Gene)
Gefitinib (Compound) upregulates ZNF589 (Gene)
Gefitinib (Compound) downregulates IFRD2 (Gene)
Gefitinib (Compound) causes Appetite absent (Side Effect)
Gefitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Danazol
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene